Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
CNBC reports that Eli Lilly and Novo are developing amylin-targeting obesity drugs to complement GLP-1 medicines. In a relatively small Phase 2 trial in patients with obesity and Type 2 diabetes, the highest-dose combination of Lilly's experimental eloralintide with tirzepatide produced 23.3% average weight loss at 48 weeks versus 14.8% on high-dose tirzepatide alone, though 10.8% to 27% stopped due to side effects. Phase 3 trials are needed.
Why it matters: Relevant to Maryland adults living with obesity and Type 2 diabetes who follow medical weight loss research, and to the clinicians who refer them for metabolic care.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to cnbc.com. October 4, 2026.